tradingkey.logo

Viatris Announces Positive Results From Phase 3 Study Of Investigational Xulane Lo™ Low Dose Patch For Birth Control In Women Of Childbearing Potential

ReutersMay 8, 2025 10:54 AM

- Viatris Inc VTRS.O:

  • VIATRIS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDY OF INVESTIGATIONAL XULANE LO™ LOW DOSE PATCH FOR BIRTH CONTROL IN WOMEN OF CHILDBEARING POTENTIAL

  • VIATRIS INC - NDA SUBMISSION TO FDA EXPECTED IN SECOND HALF OF 2025

  • VIATRIS INC - FAVORABLE SAFETY PROFILE WITH MILD-TO-MODERATE ADVERSE EVENTS

  • VIATRIS INC - XULANE LO ACHIEVES PRIMARY AND SECONDARY EFFICACY AND SAFETY ENDPOINTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI